The American Journal of Managed Care

Subcutaneous Treatments Can Save Chair Time, Decrease Infusion Reaction in NSCLC: Joshua K. Sabari, MD

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment ...
The American Journal of Managed Care

FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease

Onapgo, a subcutaneous apomorphine infusion device, is approved for advanced Parkinson's disease, offering continuous symptom management without surgery. The TOLEDO trial showed apomorphine infusion ...
Medscape

FDA OKs Novel Levodopa-Based Continuous Sub-Q Regimen for Parkinson’s

The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for ...